It’s A Deal, Finally: Dr Reddy’s Snaps Up Wockhardt’s Branded Gx Business
Executive Summary
Financially stretched Wockhardt sells select branded generic business to Dr Reddy’s for $260m, bringing the curtains down on a much anticipated transaction.
You may also be interested in...
Asia Deal Watch: Strides Obtains 18 US ANDAs From Pharmaceutics
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…
Wockhardt Will Raise Funds With Restructuring
India’s Wockhardt has announced its first profit in three years and says a restructuring plan will be carried out soon.
Dr Reddy’s Posts Surprise Q3 Loss But Strong Operating Results Boost Shares
Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge for its generic NuvaRing contraceptive but the company’s shares jumped on a robust underlying performance that analysts praised as a "great set of numbers."
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
